Replies to post #234596 on Biotech Values

[ronpopeil]

Official announcement


http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-acquire-immunomedics

[DewDiligence]

GILD reports purportedly-positive phase-3 Trodelvy data:

https://finance.yahoo.com/news/phase-3-tropics-02-study-133000097.html

However, in a companion 8-K filing today, GILD says:

https://www.sec.gov/Archives/edgar/data/0000882095/000110465922030888/tm228518d1_ex99-2.htm

We are evaluating the impact to our in-process R&D on the balance sheet, and that could impact our GAAP EPS guidance. We expect to update you on our Q1 call.

Why would GILD have to consider a balance-impairment if the trial in question was a full-fledged success? (Rhetorical.)

GILD paid $21B cash to acquire Immunomedics—and hence Trodelvy—in 2020 (#msg-158261866).

p.s. The opinion in #msg-158260565 seems to have aged well.

[swampboots]

Disastrous for shareholders. But, in short, in my opinion, all a brave spirited attempt to move the science needle risking billions against all realistic short term odds to try to "cuddle" up to having complete sovereignty over the long term effectiveness of a drug like Todelvy. From my few previous open air links regarding latest solid tumor insights, there seems to be a resounding data progression pointing to new avenues of modifying previously failed drugs to become statistically more meaningful and material.